Work

Real-World Experience of Using Dupilumab and Jak Inhibitors to Manage Pruritus in Epidermolysis Bullosa Pruriginosa

Year: 2024

Type: article

Abstract: Epidermolysis bullosa pruriginosa (EBP) is a form of dystrophic EB associated with severe pruritus and has skewed Th2 inflammation. Our study suggests that JAK inhibitors may offer superior efficacy compared to dupilumab in treating EBP. Moreover, JAK inhibitors downregulate JAK-STAT signalling and Th1/2 cell differentiation in lesional skin while not in peripheral blood.

Source: Skin Health and Disease

DOI: 10.1002/ski2.445

Authors: Ping-Chen Hou, Wilson Aala, Wei-Ting Tu, John A. McGrath, Chao-Kai Hsu

Institutions: National Cheng Kung University Hospital, National Cheng Kung University, King's College London

Language: English

Topic: Skin and Cellular Biology Research

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,403